This index is particularly useful for healthcare professionals, researchers, and individuals seeking detailed information about specific branded pharmaceutical product.
Monographs serve as essential reference for clinical particulars such as drug composition and administration guidelines, indications, contraindications and adverse reactions.
| Title | Information Source | Document Type | |
|---|---|---|---|
| RUBIFEN Immediate release tablet, Sustained release tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
| RUBILIM Prolonged release tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| RUBRACA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RUCONEST Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RUKOBIA Extended-release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RUPAFIN Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| RUPAN FEMME Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| RUPATADINE Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| RUPATADINE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| RUXIENCE Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RUZURGI Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
